Journal of the Minnesota Academy of Science
Volume 51

Number 1

Article 4

1985

The Immunology of Transplantation
J. R. Serie
Macalester College

Follow this and additional works at: https://digitalcommons.morris.umn.edu/jmas
Part of the Allergy and Immunology Commons

Recommended Citation
Serie, J. R. (1985). The Immunology of Transplantation. Journal of the Minnesota Academy of Science,
Vol. 51 No.1, 9-14.
Retrieved from https://digitalcommons.morris.umn.edu/jmas/vol51/iss1/4

This Article is brought to you for free and open access by the Journals at University of Minnesota Morris Digital
Well. It has been accepted for inclusion in Journal of the Minnesota Academy of Science by an authorized editor of
University of Minnesota Morris Digital Well. For more information, please contact skulann@morris.umn.edu.

Review Article

The Immunology of Transplantation
J.R. SERlE*

ABSTRACT - A number of life-threatening diseases, such as kidney failure, diabetes, and certain kinds of
coronary heart disease, can be cured by organ transplantation. However, despite decades of research, graft
rejection remains a very real threat to the organ transplant recipient. In attempting to develop methods that
interfere with the graft rejection process, scientists have uncovered a remarkably complex system of cellular
interactions that allows the total destruction of a transplanted organ while leaving the recipient's own organs
untouched. This ability to distinguish self from non-self is achieved through intercellular communication
involving cell-to-cell contact and the release of a number of communication molecules. This tangled web of
cellular interactions is the focus of a great deal of scientific interest since the solution to the graft rejection
problem lies in our ability to understand it. In addition, the cellular interactions that produce graft rejection may
serve as a model to help us better understand cellular communication in general.

Introduction
Organ transplantation is rapidly becoming a routine therapeutic procedure for the reversal of a number of lifethreatening diseases. Kidney transplants, the most prevalent
and successful form of organ transplantation, now result in
one-year graft survival rates of 70% to 80% for cadaver grafts
and over 90% for living related donors ( 1). More than 200
kidney transplants are performed each year at the University of
Minnesota Hospitals, which have the largest and most comprehensive organ transplant program in the world. In addition, liver, heart, bone marrow, pancreas, lung, cornea, middle
ear, and heart/lung transplants have been performed at this
center and others with increasing success. Despite these
strides, transplant patients must live with the constant threat
that their new life-saving organ will be rejected. During the
rejection process, the cells of the transplanted organ are recognized as foreign by the recipient's immune system and are
subsequently attacked and destroyed.
Under normal circumstances, it is in our best interest to
have foreign cells eliminated from our bodies. Our constant
temperature, electrolyte balance, and nutrient supply make us
superior incubators for a wide variety of infectious microorganisms, which would quickly invade and overcome our
bodies without the immune system standing guard. Unfortunately, the immune stystem does not use harmfulness as a
criterion for recognition but rather foreignness. Because the
cells of another individual are foreign, they are subject to the
same recognition and attack as the microorganisms the
immune system evolved to handle.
Beyond advances in surgical techniques and organ preservation, then, an integral component of transplantation therapy
involves attempting to thwart the ability of the recipient's
immune system to either recognize or attack the newly transplanted organ. Efforts in this area include donor-recipient
matching, in which the genetic foreignness of the donor tissue
is minimized, and the development of agents that suppress
the recipient's immune system. Unfortunately, with a suppressed immune system, the recipient becomes vulnerable to
opportunistic infections that can be life threatening. A new

generation of immunosuppressants is being developed that
attempts to suppress only those components of the immune
system that cause graft rejection while sparing those components that fight infection. However, these agents are not perfectly able to accomplish this task and are not without side
effects.
The real answer to the problem of rejection lies in our
ability to better understand the process by which grafts are
rejected. This enormously complex process remains only partially understood despite four decades of research. The problem can be divided into two major questions:
1) How does the immune system recognize transplanted tissue as foreign? and
2) Once recognition has occurred, how does the
immune system attack and destroy the foreign graft?
Because graft rejection requires both of these processes, preventing the immune system from doing either would ensure
graft survival.

Recognition of Transplanted Tissue as Foreign
The immune system uses foreignness as the sole criterion
for recognition and destruction of a cell. The effective elimination of pathogenic microorganisms requires a system that is
capable of killing living cells. Yet, our own cells must be
spared this destruction. Therefore, the immune system must
be able to differentiate self from non-self This is accomplished by the system's inability to recognize and respond to
any molecule that is a legitimate component of its own body.
Thousands of proteins and other molecules are floating free in
the body or are embedded in the outer membranes of cells.
During fetal development, the immune system is exposed to
these molecules and becomes unable to respond to them.
This tolerance of self extends only to those molecules present
during fetal life or shortly thereafter (2 ). All other molecules, if
presented to the immune system in the right fashion, will be
recognized as foreign and attacked. For example, since
microorganisms have surface molecules very different from
ours, they are easily recognized and destroyed.
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Leukocytes
The immune system is embodied in the white blood cells,
called leukocytes, and closely related cells. The immune
response is a complex set of interactions between a foreign
molecule, called an antigen, and the leukocytes. Lymphocytes, macrophages, and dendritic cells are the principal leukocytes involved in the immune response to transplanted
tissue.
The immune response begins when a surface receptor on a
lymphocyte combines with the antigen for which it is specific.
Each lymphocyte has a specific type of surface receptor with a
shape that is complementary to just one antigen. The binding
of the surface receptor and the antigen causes the lymphocyte
to begin rapidly dividing or proliferating. Once stimulated by
antigen, the various types of lymphocytes can perform their
specific roles in the process of antigen elimination. In addition, some of these lymphocytes "remember" this encounter
and, if presented with this antigen again, respond more
rapidly and extensively. This memory for past encounters is
the basis for immunization against disease.
Glycoprotein Markers
Normally, the immune system serves us well. However,
when an organ is transplanted, the immune system turns its
exquisitely sensitive and deadly power to recognize and destroy foreignness toward the newly grafted tissue. Special glycoproteins on the surface of cells are the molecules by which
the cells of the graft are recognized as foreign. Many of the
surface proteins on human cells are identical from person to
person. For instance, the membrane channel for sodium is
probably the same molecule in all members of the human
species. However, there is a set of glycoproteins present on
most cells of the body that is unique to each individual of the
species. These membrane markers are encoded by an area on
chromosome 6 called the majo~ histocompatibility complex
(MHC) (reviewed 3-5). This complex, assumed to be present
in all mammalian species, is called the HIA region (human
leukocyte antigens) in humans, and in the mouse - most
often used for investigations in this area- it is called the H-2.
In both species there are at least three extremely polymorphic, codominant loci within this area coding for the Class I
antigens - membrane-bound glycoproteins that are present
on almost all cells of the body ( 6). The Class I antigens are
encoded by the K, D, L, and R regions in the mouse and the A,
B, and C regions in the human (Figure 1) (7, 8). It has been
estimated that each of these loci may have up to 100 alleles,
making it rare for any two people to be identical at all three of
the known human loci unless they are identical twins.
Because the Class I antigens are on most of the cells of the
body, transplanted tissue bears molecules that are foreign to
the recipient's immune system.
A second area within the major histocompatibility complex
codes for glycoproteins that are found only on the surface of
lymphocytes, macrophages, dendritic cells, and a limited
number of other cells types (9-11 ). These polymorphic,
membrane-bound glycoproteins, called Class II antigens, can
be recognized as foreign by the recipient's immune system
but also probably play a key role in the interactions between
the various components of the immune system that make the
immune response possible (12). Class II antigens are
encoded by the I region of the mouse and the D region of the
human (Figure 1).
Foreignness, then, is present in two forms in transplanted
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tissue. The cells of the graft itself, for instance, kidney and liver
cells, carry foreign Class I antigens. Plus, any transplanted
lymphocytes, macrophages, or dendritic cells bear foreign
Class II antigens. These cells are very likely to be transplanted
in a graft because they reside in the fluid compartment
bathing all the cells of the body. When they are transplanted
with a graft, they are called passenger leukocytes.

Presentation of soluble antigen by adherent cells
The fact that transplanted tissue is foreign to the recipient's
immune system is only the beginning of a story that takes a
rather complex turn at this point. It has been apparent since
the early 1970s that foreignness alone is not enough to trigger
an immune response. The antigen also must be presented by
an immune system cell which, until recently, was believed to
be the macrophage. Rosenthal, eta!., used in vitro methods to
demonstrate that lymphocytes would not proliferate in the
presence of soluble antigen (as opposed to membranebound antigen) unless the antigen was associated with adherent cells (13, 14). (Adherent cells are leukocytes that will
adhere to glass or plastic.) It is now known that the adherent
population, originally thought to be entirely composed of
macrophages, also includes dendritic cells, which are probably more potent antigen presenters than macrophages ( 11,
15).
Further investigation ( 16, 17) revealed that the major histocompatibility complex plays a significant role in the presentation of soluble antigen by adherent cells in the following way:
The immune system has memory for antigens it has encountered before. When an antigen is encountered for the first
time, a primary response occurs in which lymphocytes
become primed and memory is induced. When the identical
antigen is encountered again, a secondary response occurs,
which includes lymphocyte proliferation. A secondary
response will produce much more proliferation if soluble
antigen is presented in association with an adherent cell of the
same MHC type as the one which initially presented the
antigen. For example, if antigen is presented in association
with a type A adherent cell in the primary response, a strong
secondary response will occur only if that antigen is presented
on a type A adherent cell again. If it is presented on a type B
adherent cell, the response will be poor. In other words, the
lymphocytes responding in this system remember not only
the antigen but also the major histocompatibility complex
antigens on the surface oft he cell presenting the antigen. This
phenomenon is called MHC restriction. Current evidence
suggests that the Class II antigens, found on the surface of
both macrophages and dendritic cells, are the MHC products
involved in the presentation of soluble antigen (12).
Thus, the MHC glycoprotein membrane markers on the cell
surface are probably involved in the presentation of antigen
and in the interactions of the cells oft he immune system. They
also are involved in the recognition phase of graft rejection.
Apparently, the presence of donor Class II antigen-bearing
dendritic cells is necessary for the recognition of foreignness
in transplanted tissue. Evidence for this comes from a number
of sources. One in vitro method, the mixed leukocyte reaction
(MLR), tests the ability of lymphocytes to recognize foreign
MHC antigens and to respond by proliferating. In this test,
leukocytes from one individual are mixed with leukocytes
from a second, MHC non-identical (allogeneic) individual.
Normally each set of leukocytes would see the other as foreign
and would proliferate. "A" would respond to "B," and "B"
would respond to "A." To test only one ofthese responses at a
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Figure 1. Genetic map of the major histocompatibility complex of humans and mice. The Class I antigens, present on the surface of all cells,
are encoded by the A, B, and C regions in the human and the K, 0, L, and R regions in the mouse. The Class II antigens, found on certain cells of
the immune system, are encoded by regions 0/0R in humans and the I region in mice.

time, the leukocytes from individual "A" are treated with
chemicals or irradiation to prevent their proliferation. The "A"
cells, then, are the stimulator cells. The leukocytes from individual "B" remain untreated and are the responders in this
system. Recognition of the foreign MHC antigens on the stimulator cells is manifested by the proliferation of the responding cells. When dendritic cells are specifically removed from
the stimulating leukocyte population, the proliferation of the
responding cells is significantly reduced. Further, the addition
of a small number of stimulator dendritic cells reconstitutes
the proliferation ( 17).
Numerous studies in vivo indicate that if transplanted grafts
are purged of their passenger leukocyte population, which
includes dendritic cells, either by a pre-transplant period in
tissue culture that is differentially toxic to leukocytes ( 18-20)
or by direct elimination of Class II antigen-bearing cells (21 ),
graft survival is significantly enhanced. Further, when leukocytes of donor origin are injected into recipients bearing a
surviving graft, the graft is usually subsequently rejected (22).
Thus, the presence of donor or stimulator dendritic cells
appears to be a prerequisite for graft rejection and MLR
proliferation.
It is unclear from these investigations whether the elimination of Class II antigen-bearing cells prolongs graft survival
through the elimination of MHC incompatible Class II antigens or through the elimination of the dendritic cells on
which they reside. In studies using strains of mice which
differed from one another only in very limited areas of the
MHC, it was found that if the donor and recipient are Class I
mismatched but identical at Class II, graft rejection still occurs
(23 ). Therefore, Class II incompatibility is not necessary for
graft rejection but the presence of cells bearing Class II antigens is. These findings are consistent with previous work
indicating the importance of Class II bearing dendritic cells in
antigen presentation. Although the exact role played by dendritic cells in graft rejection is not known, because they appear
to be essential to the graft rejection process, their elimination
would make grafts "invisible" to immune detection while
leaving the functioning part of the grafted tissue unharmed.
Anti-Class II antibodies are currently available that can specifi-
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cally kill these passenger cells.
There is another interesting twist to this story that complicates matters considerably - the minor histocompatibility
loci. The major histocompatibility complex is only one of
many genetic regions that cause graft rejection. The minors, as
they are called, cause a slower rejection if they are mismatched, but they can ultimately lead to the loss of a functioning graft.
Studies indicate that the minor antigens must be presented
in association with the major histocompatibility antigens in
the same fashion as soluble antigen or MHC antigens (24).
Further, researchers have found that if passenger dendritic
cells share the major histocompatibility antigens with the graft
but do not share the minor antigens, they can still present the
minors as foreign and precipitate graft rejection. However, if
the dendritic cells do not share the major histocompatibility
antigens with the graft, they cannot present the graft's minor
antigens and rejection does not occur (25). Therefore, if the
removal of dendritic cells from grafts becomes a viable
method for prolonging graft survival, it is very important that
the donor and recipient be mismatched as far as possible.
Once the graft is in place, recipient dendritic cells will invade
it and take up residence in it. If they have the same MHC as the
graft (i.e., if the donor and recipient are matched by tissue
typing), they may be able to present the minor histocompatibility differences to the recipient's immune system and precipitate rejection. It would be an ironic twist if the tissue
typing systems established to ensure the closest possible
match between donor and recipient are used in the future to
ensure the greatest mismatch or a mismatch at the specific
locus responsible for antigen presentation.

Destruction of the Transplanted Organ
Infiltration by leukocytes
The sequence of events that causes graft rejection begins
with the presentation of the graft's foreign MHC antigens to
the recipient's leukocytes, which are continually traveling
through all the organs of the body. These stimulated leuko-
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cytes migrate to local lymph nodes where they rapidly divide
and become capable of destroying the graft. When these
anti-graft effector cells are released from the local lymph
nodes into the blood, they return to the transplanted graft,
recognize the foreign MHC antigens that originally stimulated
their development, and destroy the graft cells bearing these
antigens. Once in the graft, they secrete substances that cause
a general inflammatory response in which non-specific leukocytes are attracted to the area (26).
Consequently, graft rejection is characterized by the infiltration of the graft by leukocytes. Analysis ofthe appearance and
surface markers of these cells has identified them as predominantly lymphocytes and macrophages. Further analysis of the
lymphocytes reveals the presence of both major lymphocyte
subpopulations: the B-lymphocyte (B-cell) and the T-lymphocyte (T-ee!!) (27). B-lymphocytes cause cellular destruction by secreting antibodies - large proteins that bind to the
surface markers on foreign cells -marking them for destruction by macrophages. Although B-cells make antibodies
against foreign grafted tissue (28), this antibody-mediated
form of destruction probably plays, at most, a minor role in the
typical graft rejection process. A now classic experiment demonstrated this: When antibodies against a skin graft were
injected into an animal bearing the graft, the antibodies did
not cause the graft to be rejected (29).
The T-lymphocytes found in rejecting grafts can be further
divided into two distinct subpopulations based on the presence of specific surface markers: the T- helper (TH) cells and
the T-cytotoxic (Tc) cells (27). The early investigations of the
role of each ofthese cells in graft rejection involved the use of
the mixed leukocyte reaction (MLR) described above plus an
additional test called the CML (cell-mediated lympholysis).
After a leukocyte population is stimulated to proliferate in an
MLR, the cells are transferred to a dish containing target cells,
which share the MHC antigens of the stimulator cells. Radioactive chromium has been introduced into the cytoplasm of
these target cells. If the stimulated leukocytes can kill the
target cells, the radioactive chromium is spilled into the
cuture medium and can be detected. If the leukocytes cannot
kill the targets, no radioisotope is released.
Through the use of these two tests, it was found that Thelper cells proliferated during the MLR but were unable to
kill target cells in the CML, while T-cytotoxic cells did not
proliferate during the MLR but were able to kill target cells
(30). It was also found that if T-helper cells were removed
from the population before stimulation in the MLR, the ability
ofT-cytotoxic cells to kill target cells in the CML was significantly reduced (31 ). Therefore, as their name implies, Thelper cells help T-cytotoxic cells to become capable of killing target cells.
For a number of years the MLR and CML were seen as in
vitro correlates of graft rejection. It was assumed that Tcytotoxic cells actually destroyed the graft with the help of
T-helper cells. As investigations of this system continued, an
additional division of labor between these two cell populations became apparent. Investigators found that T- helper cells
respond to differences in Class II antigens, and T-cytotoxic
cells respond to differences in Class I antigens (32). It was
hypothesized that T-helper cells were stimulated by Class II
differences in the graft to proliferate and help the T-cytotoxic
cells become capable of killing the graft. The T-cytotoxic cells
required two signals for their activation: the Class I antigens
on the surface of the stimulating cells and a signal from the
stimulated T-helper cells.
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Although the T-cytotoxic cells present in a rejecting graft are
capable of killing target cells bearing the same MHC antigens
as the graft (33 ), they are not the only killers in the population.
Non-specific cellular destruction, especially apparent in the
later stages of graft rejection ( 34), may be mediated by macrophages (35). In a type of immune reaction called a delayedtype hypersensitivity reaction (DTH), macrophages are
induced to become potent killers by factors secreted by Thelper cells (or T0 n 1 cells which, to date, cannot be distinguished from T-helper cells).
There is growing evidence that the delayed-type hypersensitivity reaction may play a major role in graft destruction (36).
Some of the most compelling evidence comes from studies in
which rats and mice bearing viable MHC disparate grafts were
deprived of their own immune systems by irradiation and
then repopulated with T-helper cells, T-cytotoxic cells, or the
two subsets together. Researchers found that reconstitution
with both subsets or T-helper cells alone caused graft rejection while reconstitution with T-cytotoxic cells did not (37).
Although we must exercise caution in interpreting these
results (38), growing evidence indicates that the T-cytotoxic
cell is not the only effector cell involved in graft destruction,
and that the macrophage, activated by the T-helper cell, may
play a major role (39, 40).

Cellular communication
Regardless of the mechanism, communication between the
cells of the immune system is a necessary prerequisite for
destruction of the graft. Dendritic cells must communicate
with responding cells during the antigen recognition process.
Similarly, T-helper cells must communicate with T-cytotoxic
cells, macrophages, and even B-lymphocytes in the process
whereby these cells become actively engaged in graft destruction. This communication probably involves some direct cellto-cell contact mediated by the surface glycoproteins of the
MHC. The cells also communicate through the release of
soluble factors which have been shown to enhance the graft
rejection process (41). For instance, T-helper cells secrete a
factor called interleukin-2 (IL-2), which is required to generate the killing ability of the T-cytotoxic cell. This is presumably
because it binds to specific receptors on the T-cytotoxic cell's
membrane, giving this cell the signal it needs to become a
killer ( 42 ). Additional evidence indicates that the presentation of antigen by the dendritic cell induces T-cytotoxic cells
to become responsive to interleukin-2 ( 43 ).
The immensely complex process by which grafts are
rejected provides an exciting model for cellular interaction in
general. The use of cell-to-cell contact and soluble factors as a
way of communicating may be a widespread method used by
many types of cells in multicellular organisms. Indeed, it has
been found that some non-immune cellular interactions
appear to be controlled by the genes of the major histocompatibilty complex or by genes that are near the complex on the
chromosome ( 44 ).

Summary: A Model
A simplified outline of the process of graft rejection is
presented in Figure 2. The process begins with the presentation of foreign MHC antigens by a stimulator cell, probably a
dendritic cell, which bears Class I and Class II MHC antigens.
T-helper cells, T-cytotoxic cells, and B-lymphocytes are all
stimulated by this antigen presentation. The T-helper cell is
stimulted by the Class II antigens, the T-cytotoxic cell by the
Class I antigens, and the B-lymphocyte by both. Before they
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can respond, however, each needs a second signal. The Thelper cell receives its second signal in the form of a soluble
factor, called co-stimulator by Lafferty ( 45 ), which the dendritic cell secretes when the T-helper cell binds to it. This
soluble factor is very possibly interleukin-1. Once it has
received both signals, the T-helper cell rapidly divides and
secretes a second soluble factor, interleukin-2. This factor
provides the second signal to the T-cytotoxic cell, which can
then develop the ability to kill by cell-to-cell contact cells
bearing the original Class I antigens.
In addition to interleukin-2, stimulated T-helper cells also
release macrophage activating factors, which cause macrophages to become active, though non-specific, killers. The
T-he! per cells also secrete B-ee!! growth factors, which cause
stimulated B-lymphocytes to develop into cells that secrete
antibodies. The antibodies can then bind to the Class I antigens on the surface of the graft cells and mark them for
specific destruction by an activated macrophage.
We are just beginning to clearly define the details of these
cellular interactions. As investigations continue and more of
these interactions are understood, our power to interfere with
this process without harming the graft recipient will increase
dramatically. There is hope that we can develop procedures
through this research that will make organ transplantation a
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